GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Nanosphere Inc (NAS:NSPH) » Definitions » Debt-to-Equity

Nanosphere (Nanosphere) Debt-to-Equity : 1.67 (As of Mar. 2016)


View and export this data going back to 2007. Start your Free Trial

What is Nanosphere Debt-to-Equity?

Nanosphere's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2016 was $20.55 Mil. Nanosphere's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2016 was $0.00 Mil. Nanosphere's Total Stockholders Equity for the quarter that ended in Mar. 2016 was $12.29 Mil. Nanosphere's debt to equity for the quarter that ended in Mar. 2016 was 1.67.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Nanosphere's Debt-to-Equity or its related term are showing as below:

NSPH's Debt-to-Equity is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 0.23
* Ranked among companies with meaningful Debt-to-Equity only.

Nanosphere Debt-to-Equity Historical Data

The historical data trend for Nanosphere's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanosphere Debt-to-Equity Chart

Nanosphere Annual Data
Trend Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15
Debt-to-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.27 0.36 0.83

Nanosphere Quarterly Data
Jun11 Sep11 Dec11 Mar12 Jun12 Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.46 0.66 1.07 0.83 1.67

Competitive Comparison of Nanosphere's Debt-to-Equity

For the Diagnostics & Research subindustry, Nanosphere's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nanosphere's Debt-to-Equity Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Nanosphere's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Nanosphere's Debt-to-Equity falls into.



Nanosphere Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Nanosphere's Debt to Equity Ratio for the fiscal year that ended in Dec. 2015 is calculated as

Nanosphere's Debt to Equity Ratio for the quarter that ended in Mar. 2016 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nanosphere  (NAS:NSPH) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Nanosphere Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Nanosphere's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Nanosphere (Nanosphere) Business Description

Traded in Other Exchanges
N/A
Address
Nanosphere, Inc., was incorporated in 1999 in Delaware. The Company develops, manufactures and markets an advanced molecular diagnostics platform, the Verigene System, that enables sensitive genomic and protein testing on a single platform. The Verigene System includes a bench-top molecular diagnostics workstation that is an advanced platform for genomic and protein testing. The Verigene System includes a bench-top molecular diagnostics workstation that is a universal platform for genomic and protein testing. The Verigene System provides lower cost for laboratories already performing molecular diagnostic testing and enables smaller laboratories and hospitals without advanced diagnostic capabilities to perform genetic testing.
Executives
Michael James Ward director 440 W. ONTARIO ST., CHICAGO IL 60654
Lorin Randall director C/O ACORDA THERAPEUTICS, INC., 420 SAW MILL RIVER ROAD, ARDSLEY NY 10502
R. Erik Holmlin director 4088 COMMERCIAL AVE., NORTHBROOK IL 60062
Gene S Cartwright director 4088 COMMERCIAL AVE, NORTHBROOK IL 60062
Mmcap International Inc. Spc 10 percent owner C/O MOURANT GOVERNANCE SVCS (CAYMAN) LTD, 94 SOLARIS AVE., CAMANA BAY, PO BOX 1348, GRAND CAYMAN E9 KY1-1108
Ann Wallin officer: Interim CFO 4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062
Bruin Andre De director
Sheli Z Rosenberg director C/O EQUITY GROUP INVESTMENTS, L.L.C., TWO NORTH RIVERSIDE PLAZA, SUITE 600, CHICAGO IL 60606
Chad A. Mirkin director 4088 COMMERCIAL AVENUE, NORTHBROOK IL 60062
Brookside Capital Management Llc 10 percent owner C/O BAIN CAPITAL PUBLIC EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02116
Brookside Capital Partners Fund Lp 10 percent owner C/O BAIN CAPITAL PUBLIC EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02116
Brookside Capital Investors L P 10 percent owner C/O BAIN CAPITAL PUBLIC EQUITY, LP, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Venture Fund 2005, L.p. 10 percent owner C/O BAIN CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Venture Partners 2005, L.p. 10 percent owner C/O BAIN CAPITAL, LLC, JOHN HANCOCK TOWER, 200 CLARENDON STREET, BOSTON MA 02116
Bain Capital Venture Investors, Llc 10 percent owner 200 CLARENDON STREET, BOSTON MA 02116

Nanosphere (Nanosphere) Headlines

From GuruFocus

NANOSPHERE, INC. Reports Operating Results (10-Q)

By gurufocus 10qk 11-05-2009

NANOSPHERE, INC. Reports Operating Results (10-Q)

By gurufocus 10qk 05-06-2010

NANOSPHERE, INC. Reports Operating Results (10-Q)

By gurufocus 10qk 08-05-2010

New Optical Disks May Boost the Gold Nanoparticles Industry

By Alberto Abaterusso Alberto Abaterusso 03-27-2018